Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma

Development of anti-drug antibodies (ADAs) can interfere with therapeutic monoclonal antibodies and may lead to drug neutralisation and clinical disease progression. Measurement of circulating drug levels and development of ADAs in the setting of anti-programmed cell death-1 agent pembrolizumab has...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasson, S. C., Wilkins, L. E., Watson, R. A., Jolly, C., Brain, O., Klenerman, P., Olsson-Brown, A., Fairfax, B. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478874/
https://www.ncbi.nlm.nih.gov/pubmed/34584157
http://dx.doi.org/10.1038/s41598-021-98700-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478874/
https://www.ncbi.nlm.nih.gov/pubmed/34584157
http://dx.doi.org/10.1038/s41598-021-98700-7

Ejemplares similares